Article

Tisotumab Vedotin Shows Clinical Benefit and Ongoing Responses in Cervical Cancer

A first-in-human study showed that the antibody drug conjugate tisotumab vedotin was well-tolerated and provided promising anti-tumor activity in patients with relapsed, recurrent, and/or metastatic cervical cancer.

A first-in-human study showed that the antibody drug conjugate (ADC) tisotumab vedotin (HuMax®-TF-ADC) was well-tolerated and provided promising anti-tumor activity in patients with relapsed, recurrent, and/or metastatic cervical cancer, according to findings presented in a poster at the European Society of Gynaecological Oncology (ESGO) 2017 Congress.

Tisotumab vedotin is composed of a human monoclonal antibody that is specific for human tissue factor (TF) and is covalently coupled via a protease-cleavable peptide linker to monomethyl auristatin E (MMAE). MMAE is a potent microtubule disrupting agent that results in cell cycle arrest at the G2/M phase and apoptosis. TF is a transmembrane protein involved in angiogenesis, cell adhesion, motility, and cell survival, and is aberrantly over-expressed across a broad range of solid tumors, including cervical cancer, according to the poster authors.

“TF expression has been associated with a poor prognosis in cervical cancer; tisotumab vedotin selectively targets TF to deliver a clinically validated toxic payload to tumor cells, said Nicole Concin, MD, of the oncology department at the University Hospital Leuven in Leuven, Belgium, during a poster discussion session.

Tisotumab vedotin was evaluated in the cervical cancer expansion cohort of the open label, single arm, phase IIa GEN701 trial (NCT02001623). Thirty-four patients with relapsed, recurrent, and/or metastatic cervical cancer received tisotumab vedotin at 2.0 mg/kg administered by IV every 3 weeks. The primary objectives were safety and tolerability while secondary objectives included preliminary antitumour activity according to RECIST v1.1 as evaluated by CT scans done every 6 weeks.

The patients had a median age of 43 years and 21% of patients had an ECOG performance status of 0, and 76% had 1. The majority (44% each) of patients had adenocarcinoma or squamous cell cancer, 3 (9%) patients had adeno-squamous, and the cancer type was missing for 1 (3%) patient. Overall, 91% of patients had received prior treatment with a platinum- and/or taxane-based chemotherapy regimen, and 71% had received prior bevacizumab (Avastin).

The safety analysis showed compound-specific conjunctival toxicity that could be resolved with prophylactic steroid lubricating eye drops and cooling eye masks worn during treatment infusion. Prior to mitigation, 73% of patients experienced conjunctivitis of any grade. After mitigation, 32% of patients experienced any grade conjunctivitis and 5% of patients reported grade ≥3 conjunctivitis.

“Compound-specific conjunctival events were observed; however, mitigation measures substantially the reduced rates of toxicity,” she remarked.

Other frequently occurring treatment emergent adverse events (TEAEs) of any grade included epistaxis, fatigue, and alopecia, each in 47% of patients, and nausea in 44% of patients.

Grade 3 TEAEs were reported in 16 (47%) patients, and included vomiting in 15% of patients, while 9% of patients each reported grade 3 abdominal pain, nausea, and fatigue. There were no grade 4/5 events

“The safety profile of tisotumab vedotin in recurrent cervical cancer was generally consistent with other MMAE-based ADCs,” she pointed out.

Study discontinuation was reported for 27 (79%) patients. Five patients withdrew due to an AE, 16 due to disease progression, and 6 patients for other reasons.

Efficacy results after 12 weeks of treatment revealed 50% of patients showed clinical benefit. Eleven patients showed tumor reduction for an overall response rate of 32% including 8 confirmed and 3 unconfirmed partial responses. Tumor reduction from baseline was 40% or greater in all 11 responding patients, 3 patients showed tumor size reduction over 60%, and 80% tumor reduction was observed in 1 patient.

Stable disease was achieved by 6 patients, yielding a disease control rate (DCR) of 50%.

In responding patients, the median duration of confirmed responses was 8.3 months. Seven (21%) patients remain on treatment.

“Tisotumab vedotin demonstrated robust efficacy and a manageable safety profile in the cervical cancer expansion cohort,” Concin said. “The substantial efficacy and the manageable safety profile warrant further development of tisotumab vedotin in previously treated recurrent/advanced cervical cancer.”

The authors noted that an additional dosing schedule is being evaluated in a cervical cancer expansion cohort in the GEN702 study (NCT02552121).

Concin N, Vergote I, Dean E, et al. A phase IIa study of tisotumab vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer: updated safety and efficacy. Poster presented at: 2017 ESGO Congress; November 4-7, 2017; Vienna, Austria.

Related Videos
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Mikkael A. Sekeres, MD, discusses the results of combining luspatercept and lenalidomide in lower-risk, non–5q deletion myelodysplastic syndromes.
Prithviraj Bose, MD, and Chandler Park, MD, FACP
David Samuel Dicapua Siegel, MD
Laahn Foster, MD
Christine Mauz-Koerholz, MD, PhD
Marcella Ali Kaddoura, MD
Wojciech Jurczak, MD, PhD
Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.